2023
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial
Ross J, Perumal R, Wolf A, Zulu M, Guzman K, Seepamore B, Reis K, Nyilana H, Hlathi S, Narasimmulu R, Cheung Y, Amico K, Friedland G, Daftary A, Zelnick J, Naidoo K, O’Donnell M. Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial. Trials 2023, 24: 776. PMID: 38037105, PMCID: PMC10691086, DOI: 10.1186/s13063-023-07520-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsHIV InfectionsHumansProspective StudiesRandomized Controlled Trials as TopicSouth AfricaTreatment OutcomeTuberculosis, Multidrug-ResistantConceptsMultidrug-resistant tuberculosisAdherence support interventionsAntiretroviral therapyTreatment regimensAdherence supportPrimary outcomeTreatment supportPsychosocial supportMDR-TB treatment regimensUndetectable HIV viral loadSupport interventionsIntegrase strand transfer inhibitorsAdherence support strategiesComposite clinical outcomeMDR-TB regimensNegative TB culturesCombination antiretroviral therapyComposite primary outcomeHIV treatment outcomesHIV viral loadDrug-resistant tuberculosisStandard of careNew treatment regimensDifferentiated service deliveryStrand transfer inhibitors
2022
Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS
O'Donnell MR, Padayatchi N, Wolf A, Zelnick J, Daftary A, Orrell C, Nimmo C, Baldwin M, Boodhram R, Maharaj B, Amico KR, Naidoo K, Friedland G. Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 90: 325-332. PMID: 35195572, PMCID: PMC11077859, DOI: 10.1097/qai.0000000000002940.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAntitubercular AgentsDiarylquinolinesElectronicsHIV InfectionsHumansProspective StudiesSouth AfricaTreatment OutcomeTuberculosis, Multidrug-ResistantConceptsMDR-TB treatment outcomesResistance-associated variantsTreatment outcomesAntiretroviral therapyMDR-TBART adherenceMultidrug-resistant tuberculosis treatmentHIV treatment outcomesProspective cohort studyMultidrug-resistant tuberculosisEnd of treatmentTreatment of patientsSuccessful treatment outcomeElectronic dose monitoring devicesHIV/AIDSCohort studyClinical outcomesMultivariable analysisNovel regimensMedication adherenceAdherence thresholdTuberculosis treatmentTreatment completionLow adherenceDose monitoringAdherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis
Bateman M, Wolf A, Chimukangara B, Brust JCM, Lessells R, Amico R, Boodhram R, Singh N, Orrell C, Friedland G, Naidoo K, Padayatchi N, O’Donnell MR. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases 2022, 75: 1489-1496. PMID: 35352097, PMCID: PMC9617578, DOI: 10.1093/cid/ciac232.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-Retroviral AgentsAntitubercular AgentsElectronicsHIVHIV InfectionsHumansProspective StudiesSouth AfricaTuberculosis, Multidrug-ResistantConceptsMultidrug-resistant tuberculosisHuman immunodeficiency virusMDR-TB treatmentART adherenceART resistanceHuman immunodeficiency virus/AIDSEmergent resistanceStandard of careResource-limited settingsTB regimensAntiretroviral resistanceHIV RNAProspective cohortMedication adherenceImmunodeficiency virusPoor outcomeShort followAdherence thresholdCopies/Treatment outcomesDose monitoringResistance mutationsResistance testingPublic hospitalsLinear association
2019
Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection
O'Donnell MR, Padayatchi N, Daftary A, Orrell C, Dooley KE, Amico K, Friedland G. Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. The Lancet HIV 2019, 6: e201-e204. PMID: 30846058, PMCID: PMC7155388, DOI: 10.1016/s2352-3018(19)30035-9.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Retroviral AgentsAntitubercular AgentsCoinfectionDiarylquinolinesDrug SubstitutionFemaleHIV InfectionsHumansMaleMedication AdherenceNevirapineSouth AfricaTuberculosis, Multidrug-ResistantConceptsDrug-resistant tuberculosisBedaquiline treatmentTuberculosis-HIVLow antiretroviral therapy adherencePotent new therapyAntiretroviral therapy initiationAntiretroviral therapy adherenceEfavirenz-containing regimensFixed-dose combinationAntiretroviral therapy switchMiddle-income settingsDaily nevirapineAdherence supportAntiretroviral resistanceAntiretroviral therapyHIV patientsTherapy initiationViral failureTherapy switchImproved survivalTherapy adherenceDrug interactionsNew therapiesHIVBedaquiline
2018
Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa
Bionghi N, Daftary A, Maharaj B, Msibi Z, Amico K, Friedland G, Orrell C, Padayatchi N, O’Donnell M. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa. BMC Infectious Diseases 2018, 18: 171. PMID: 29642874, PMCID: PMC5896111, DOI: 10.1186/s12879-018-3080-2.Peer-Reviewed Original ResearchConceptsAnti-retroviral therapySeven-day recallPill countMedication adherenceWisepill deviceTreatment regimensTB/HIV co-infected patientsHIV co-infected adultsHIV co-infected patientsDrug-resistant tuberculosis treatmentCo-infected adultsCo-infected patientsDR-TB treatmentPilot study patientsWeekly pill countsComplex treatment regimensElectronic pill boxesLevel of adherenceTB regimensAdherence supportAntiretroviral therapyHIV patientsStudy patientsMethodsEligible patientsNew antimycobacterial drugs
2016
Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV
O'Donnell MR, Daftary A, Frick M, Hirsch-Moverman Y, Amico KR, Senthilingam M, Wolf A, Metcalfe JZ, Isaakidis P, Davis JL, Zelnick JR, Brust JC, Naidu N, Garretson M, Bangsberg DR, Padayatchi N, Friedland G. Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV. The International Journal Of Tuberculosis And Lung Disease 2016, 20: 430-434. PMID: 26970149, PMCID: PMC4863995, DOI: 10.5588/ijtld.15.0360.Peer-Reviewed Original ResearchMeSH KeywordsCoinfectionDirectly Observed TherapyHIV InfectionsHumansMedication AdherencePatient Education as TopicPatient-Centered CareTuberculosis, Multidrug-ResistantConceptsHuman immunodeficiency virusDrug-resistant TBMedication adherenceNational TB Control ProgrammeDrug-resistant tuberculosisTB control programsPatient-centered modelPatient-centered careNew antimycobacterial agentsUnderstanding of adherenceHealth care systemAdherence supportTB-HIVObserved therapyImmunodeficiency virusComprehensive careTreatment outcomesTreatment supportTuberculosis diagnosticsPatientsCare systemCareAntimycobacterial agentsTreatment deliveryAdherence
2014
Minimal Diversity of Drug-Resistant Mycobacterium tuberculosis Strains, South Africa - Volume 20, Number 3—March 2014 - Emerging Infectious Diseases journal - CDC
Gandhi NR, Brust JC, Moodley P, Weissman D, Heo M, Ning Y, Moll AP, Friedland GH, Sturm AW, Shah NS. Minimal Diversity of Drug-Resistant Mycobacterium tuberculosis Strains, South Africa - Volume 20, Number 3—March 2014 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2014, 20: 394-401. PMID: 24565645, PMCID: PMC3944869, DOI: 10.3201/eid2003.131083.Peer-Reviewed Original ResearchConceptsXDR-TB casesMDR-TBXDR-TBTB casesDrug-resistant Mycobacterium tuberculosis strainsInfectious Diseases journal - CDCDrug-susceptible TBDrug-resistant tuberculosisNon-Beijing strainsDrug-susceptible isolatesMycobacterium tuberculosis strainsStrain typesStrain prevalenceRetrospective studyHigh incidenceBeijing strainsTuberculosis strainsSpoligotype patternsPredominant strainMultidrugStrongest predictorMortalityTBSurvivalHIVImproved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial
Padayatchi N, Abdool Karim SS, Naidoo K, Grobler A, Friedland G. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. The International Journal Of Tuberculosis And Lung Disease 2014, 18: 147-154. PMID: 24429305, PMCID: PMC4770013, DOI: 10.5588/ijtld.13.0627.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-HIV AgentsAntitubercular AgentsCD4 Lymphocyte CountCoinfectionFemaleHIV InfectionsHumansKaplan-Meier EstimateMaleMiddle AgedSouth AfricaTime FactorsTreatment OutcomeTuberculosis, Multidrug-ResistantConceptsMultidrug-resistant tuberculosisMDR-TB patientsSequential treatment armAnti-tuberculosis treatmentAntiretroviral treatmentTreatment armsFirst-line anti-tuberculosis treatmentMultidrug-resistant tuberculosis patientsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionOut-patient clinicDrug susceptibility resultsSAPiT trialTuberculosis patientsClinical outcomesEarly initiationTherapeutic effectVirus infectionMortality ratePatientsTherapeutic outcomesSmall sample sizeTreatmentSusceptibility resultsTuberculosis
2013
Chest Radiograph Findings and Time to Culture Conversion in Patients with Multidrug-Resistant Tuberculosis and HIV in Tugela Ferry, South Africa
Brust JC, Berman AR, Zalta B, Haramati LB, Ning Y, Heo M, van der Merwe TL, Bamber S, Moll AP, Friedland GH, Shah NS, Gandhi NR. Chest Radiograph Findings and Time to Culture Conversion in Patients with Multidrug-Resistant Tuberculosis and HIV in Tugela Ferry, South Africa. PLOS ONE 2013, 8: e73975. PMID: 24040132, PMCID: PMC3765317, DOI: 10.1371/journal.pone.0073975.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsCD4 Lymphocyte CountCoinfectionDrug Therapy, CombinationFemaleHIV InfectionsHumansMaleRadiography, ThoracicSouth AfricaSputumTreatment OutcomeTuberculosis, Multidrug-ResistantConceptsMultidrug-resistant tuberculosisBaseline chest radiographSputum smear statusCulture conversionMajority of patientsCD4 countHilar lymphadenopathySmear statusPleural effusionSputum smearChest radiographsAntiretroviral therapy eraCulture conversion rateMedian CD4 countPercent of patientsChest radiograph findingsEnd of treatmentTherapy eraAdvanced immunodeficiencyCavitary diseaseRadiograph findingsHIV statusRadiographic featuresIndependent associationTreatment outcomesTransmission of Tuberculosis in Resource-Limited Settings
Kompala T, Shenoi SV, Friedland G. Transmission of Tuberculosis in Resource-Limited Settings. Current HIV/AIDS Reports 2013, 10: 264-272. PMID: 23824469, PMCID: PMC3809054, DOI: 10.1007/s11904-013-0164-x.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsCommunity-Acquired InfectionsCross InfectionHealth FacilitiesHumansSouth AfricaTuberculosisTuberculosis, Multidrug-ResistantConceptsDrug-resistant TBTB transmissionCommunity settingsInfection controlHigh HIV prevalenceInfection control practicesTransmission of tuberculosisHousehold contact tracingResource limited settingsHealth care facilitiesResource-constrained settingsHIV prevalenceTB epidemicContinued transmissionCommon siteUnrecognized transmissionContact tracingCommunity sitesControl practicesHold promiseRecent studiesTransmission reductionIntensive caseSettingTBA Pilot Study of an mHealth Application for Healthcare Workers: Poor Uptake Despite High Reported Acceptability at a Rural South African Community-Based MDR-TB Treatment Program
Chaiyachati KH, Loveday M, Lorenz S, Lesh N, Larkan LM, Cinti S, Friedland GH, Haberer JE. A Pilot Study of an mHealth Application for Healthcare Workers: Poor Uptake Despite High Reported Acceptability at a Rural South African Community-Based MDR-TB Treatment Program. PLOS ONE 2013, 8: e64662. PMID: 23724075, PMCID: PMC3665589, DOI: 10.1371/journal.pone.0064662.Peer-Reviewed Original ResearchMeSH KeywordsAdultCell PhoneFemaleHealth CommunicationHealth PersonnelHumansMaleMiddle AgedPatient Acceptance of Health CarePilot ProjectsRural PopulationSouth AfricaTuberculosis, Multidrug-ResistantConceptsAdverse event formsMDR-TB patientsMDR-TB therapyHealthcare workersMobile healthcare workersMDR-TB treatment programmeMultidrug-resistant tuberculosis epidemicPoor uptakeAdverse clinical eventsResource-poor settingsRural South African communityEvent formsMixed-methods evaluationClinical eventsSpecialty centersCommunity hospitalHCWs' perceptionsTuberculosis epidemicOwn careIntensive phaseHealth professionalsHealth interventionsPoor settingsTreatment programQualitative focus groupsAdverse Events in an Integrated Home-Based Treatment Program for MDR-TB and HIV in KwaZulu-Natal, South Africa
Brust JC, Shah NS, van der Merwe TL, Bamber S, Ning Y, Heo M, Moll AP, Loveday M, Lalloo UG, Friedland GH, Gandhi NR. Adverse Events in an Integrated Home-Based Treatment Program for MDR-TB and HIV in KwaZulu-Natal, South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 62: 436-440. PMID: 23254152, PMCID: PMC3641171, DOI: 10.1097/qai.0b013e31828175ed.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsHIV InfectionsHome Care ServicesHumansSouth AfricaTuberculosis, Multidrug-ResistantConceptsMultidrug-resistant tuberculosisAdverse eventsAntiretroviral therapyCommon severe adverse eventsMDR-TB/HIVTreatment programConcurrent antiretroviral therapyMDR-TB patientsMDR-TB therapySevere adverse eventsHome-based treatment programHome-based care settingsRural KwaZulu-NatalMost patientsTherapy modificationConcurrent treatmentCare settingsHIVPatientsTherapyKwaZulu-NatalIntegrated HomeTolerabilityHypothyroidismTuberculosis
2012
Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care [Perspectives]
Brust J, Shah N, Scott M, Chaiyachati K, Lygizos M, van der Merwe T, Bamber S, Radebe Z, Loveday M, Moll A, Margot B, Lalloo U, Friedland G, Gandhi N. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care [Perspectives]. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 998-1004. PMID: 22668560, PMCID: PMC3390442, DOI: 10.5588/ijtld.11.0713.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmbulatory CareAnti-HIV AgentsAntitubercular AgentsAttitude of Health PersonnelCaregiversCD4 Lymphocyte CountCoinfectionDelivery of Health Care, IntegratedFeasibility StudiesFemaleHealth Knowledge, Attitudes, PracticeHIV InfectionsHome Care ServicesHumansMaleMedication AdherenceOrganizational ObjectivesPatient Care TeamProgram DevelopmentProgram EvaluationRural Health ServicesSocial SupportSouth AfricaTime FactorsTreatment OutcomeTuberculosis, Multidrug-ResistantViral LoadConceptsMultidrug-resistant tuberculosisHome-based treatmentHIV treatmentAdverse reactionsTreatment outcomesTreatment programHigh HIV prevalent settingsMDR-TB treatmentEscalation of careSevere adverse eventsHIV treatment programsHIV-prevalent settingsCommunity health workersCo-infection ratePatient treatment programTreatment modelPromising treatment modelNew treatment modelRural KwaZulu-NatalHIV-coMonthly culturesAdherence supportAdverse eventsClinical responseHIV outcomesTuberculosis infection control in a high drug-resistance setting in rural South Africa: Information, motivation, and behavioral skills
Kanjee Z, Amico KR, Li F, Mbolekwa K, Moll AP, Friedland GH. Tuberculosis infection control in a high drug-resistance setting in rural South Africa: Information, motivation, and behavioral skills. Journal Of Infection And Public Health 2012, 5: 67-81. PMID: 22341846, DOI: 10.1016/j.jiph.2011.10.008.Peer-Reviewed Original ResearchConceptsTB infection controlRural South African hospitalSouth African hospitalsInfection controlHIV statusAfrican hospitalsTuberculosis infection controlDrug-resistant tuberculosisBehavioral skillsCough hygieneSocial support itemsPresent studyRural South AfricaResource-limited facilitiesHigh-risk areasAnonymous questionnaireIMB modelTuberculosisRespondents' knowledgeSuch interventionsHospitalHCWsIC practicesMost respondentsSocial supportRisk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting
Gandhi N, Andrews J, Brust J, Montreuil R, Weissman D, Heo M, Moll A, Friedland G, Shah N. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 90-97. PMID: 22236852, PMCID: PMC3302205, DOI: 10.5588/ijtld.11.0153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntitubercular AgentsCD4 Lymphocyte CountCoinfectionDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisFemaleHIV InfectionsHumansMaleMarkov ChainsMonte Carlo MethodPrevalencePrognosisProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsSouth AfricaSurvival AnalysisTime FactorsTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryConceptsHuman immunodeficiency virusXDR-TB patientsRisk factorsAntiretroviral therapyXDR-TBDrug-resistant (XDR) TBImmunosuppressed human immunodeficiency virusStrong independent risk factorHigh HIV prevalence settingsMDR-TB patientsTB treatment programsIndependent risk factorYear of diagnosisDrug-resistant tuberculosisHIV prevalence settingsCells/Principal risk factorsCase-control studyAmplification of resistanceHigh mortality rateART initiationHIV testingImmunodeficiency virusPrevalence settingsMortality rate
2011
Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting
Vella V, Racalbuto V, Guerra R, Marra C, Moll A, Mhlanga Z, Maluleke M, Mhlope H, Margot B, Friedland G, Shah N, Gandhi N. Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting. The International Journal Of Tuberculosis And Lung Disease 2011, 15: 1170-1175. PMID: 21943840, DOI: 10.5588/ijtld.10.0781.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntitubercular AgentsExtensively Drug-Resistant TuberculosisFamily CharacteristicsFemaleFollow-Up StudiesHIV InfectionsHumansIncidenceMaleMicrobial Sensitivity TestsMiddle AgedPrevalenceProspective StudiesSouth AfricaTime FactorsTuberculosis, Multidrug-ResistantYoung AdultConceptsDrug-resistant tuberculosisHousehold contactsXDR-TBIndex caseMDR-TBPrevalence settingsHigh human immunodeficiency virus (HIV) prevalence settingsMDR-TB index casesHigh HIV prevalence settingsAdult household contactsHousehold contact investigationIndex case diagnosisMost secondary casesHIV prevalence settingsRate of MDRDrug susceptibility testingDiagnosis of MDRPublic health activitiesActive tuberculosisNosocomial transmissionContact investigationMedian timeIncidence rateSecondary casesObservational studyIncreasing Drug Resistance in Extensively Drug-Resistant Tuberculosis, South Africa - Volume 17, Number 3—March 2011 - Emerging Infectious Diseases journal - CDC
Shah NS, Richardson J, Moodley P, Moodley S, Babaria P, Ramtahal M, Heysell SK, Li X, Moll AP, Friedland G, Sturm AW, Gandhi NR. Increasing Drug Resistance in Extensively Drug-Resistant Tuberculosis, South Africa - Volume 17, Number 3—March 2011 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2011, 17: 510-513. PMID: 21392446, PMCID: PMC3166021, DOI: 10.3201/eid1703.101363.Peer-Reviewed Original ResearchConceptsExtensively Drug-Resistant TuberculosisTuberculosis drug susceptibility testingDrug-resistant Mycobacterium tuberculosisInfectious Diseases journal - CDCDrug-resistant TBDrug-resistant tuberculosisDrug susceptibility testingEffective treatmentAvailable drugsDrug resistanceSusceptibility testingMycobacterium tuberculosisTuberculosisDrugsPatientsRapid Diagnosis of Tuberculosis and Multidrug Resistance by the Microscopic-Observation Drug-Susceptibility Assay
Shah NS, Moodley P, Babaria P, Moodley S, Ramtahal M, Richardson J, Heysell S, Li X, Moll A, Friedland G, Sturm AW, Gandhi NR. Rapid Diagnosis of Tuberculosis and Multidrug Resistance by the Microscopic-Observation Drug-Susceptibility Assay. American Journal Of Respiratory And Critical Care Medicine 2011, 183: 1427-1433. PMID: 21297071, DOI: 10.1164/rccm.201009-1449oc.Peer-Reviewed Original ResearchConceptsDrug susceptibility testingMDR-TB diagnosisMDR-TBHIV statusMultidrug-resistant (MDR) TBProportion methodRapid diagnosisProspective diagnostic accuracy studyAdult TB suspectsMicroscopic-Observation DrugReference standard cultureMedian CD4 countPatient's HIV statusHIV prevalence settingsIndirect proportion methodMycobacterial growth indicator tube (MGIT) cultureMedian turnaround timeResource-limited settingsReference standardDiagnostic accuracy studiesCD4 countMycobacterium tuberculosis detectionConsecutive adultsTB suspectsHIV prevalenceCulture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa
Brust JC, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, Moll AP, Li X, Loveday M, Bamber SA, Lalloo UG, Friedland GH, Shah NS, Gandhi NR. Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa. PLOS ONE 2011, 6: e15841. PMID: 21253585, PMCID: PMC3017058, DOI: 10.1371/journal.pone.0015841.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsAntitubercular AgentsFemaleHIV InfectionsHumansMaleRemission InductionRetrospective StudiesSouth AfricaSputumTime FactorsTuberculosis, Multidrug-ResistantYoung AdultConceptsMDR-TB patientsCulture conversion rateMDR-TB treatmentMonths of therapyAntiretroviral therapyHIV-coCulture conversionHIV co-infected patientsMultidrug-resistant tuberculosis patientsTiming of ARTMDR-TB therapyCo-infected patientsHIV-negative patientsSecond-line regimenSimilar cure ratesDays of initiationResource-limited settingsHIV prevalentART medicationsCD4 countMDR-TBTuberculosis patientsSputum cultureSuch patientsHIV status
2010
Predictors of Multidrug- and Extensively Drug-Resistant Tuberculosis in a High HIV Prevalence Community
Andrews JR, Shah NS, Weissman D, Moll AP, Friedland G, Gandhi NR. Predictors of Multidrug- and Extensively Drug-Resistant Tuberculosis in a High HIV Prevalence Community. PLOS ONE 2010, 5: e15735. PMID: 21209951, PMCID: PMC3012092, DOI: 10.1371/journal.pone.0015735.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisTB treatment failureXDR-TBHIV prevalence settingsRisk factorsTreatment failureOdds ratioMDR/XDR-TBOnly significant risk factorRetrospective case-control studyDrug resistanceMDR-TB patientsSignificant risk factorsStrong risk factorMultivariate logistic regressionTB drug resistanceCase-control studyHigh HIV prevalence communitiesDemographic risk factorsDrug susceptibility testing methodsHIV prevalence communitiesTB settingsClinical deteriorationMDR-TBTB treatment